Vieworks Co. Ltd (100120) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Vieworks Co. Ltd stock KRW 35,295, price KRW 27,900, upside +26.5%, quality 61 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 17,526 KRW – 41,468 KRW · fair‑value band 20,913 KRW – 56,161 KRW · the 27,900 KRW price screens below the 35,295 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Vieworks Co. in your weekly email
Every Wednesday you see whether Vieworks Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vieworks Co., Ltd. develops, manufactures, and sells imaging systems and solutions.
Show moreShow less
The company offers X-ray detectors and image processing technologies for general radiography system, dental and surgical C-arm systems, radiography and fluoroscopy system, veterinary radiography system, industrial inspection instrument, and other applications.
It also provides industrial cameras; and bio imaging systems comprising in vivo imaging systems under the VISQUE brand. The company was formerly known as Raysis Co., Ltd. and changed its name to Vieworks Co., Ltd. in November 2006.
Vieworks Co., Ltd. was founded in 1999 and is headquartered in Anyang-si, South Korea.
Stock analysis
Vieworks Co. Ltd (100120) currently trades at 27,900 KRW, while our model-based Fair Value estimate is 35,295 KRW, implying the stock looks roughly 21% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 44,276 KRW per share, and 14 of the 25 models we run sit above the 27,900 KRW price.
Bear case: the Dividend Discount group reads lowest at 7,969 KRW, and 11 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 20,913 KRW (bear) to 56,161 KRW (bull), the price of 27,900 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vieworks Co. Ltd reported revenue of 239B KRW in FY2025 versus 193B KRW in FY2021, a compound +5.5%/yr. Reported net income was 22.0B KRW in FY2025, compounding −10.0%/yr from FY2021.
Key figures
Market cap 250B KRW (≈ $185M) Micro · P/E ratio 5.4 · P/S ratio 1.03 · EPS (TTM) 5,050 KRW · Dividend yield 2.5% · Net margin 17.8% · Return on equity 17.3% · Return on assets (EBIT) 9.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 59% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 27%, 100120 screens cheaper than that median.
Fair Value models
Bear20,913 KRWFair Value 35,295 KRWBull56,161 KRW
Price 27,900 KRW · Upside +26.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3,739 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Start year 2020 (pandemic). Over 10 years: +9.9% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.1%
Dividend (yield on the price)2.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.1% vs −1.0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +22.4% a year for the price and +2.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+26.5% · Top 25%
Profitability
Return on equity (12 months)17.3% · Top 25%
Return on assets6.2% · Above median
Net margin (12 months)17.8% · Top 25%
Operating margin (12 months)16.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)1.9% · Below median
Dividend yield (12 months)2.5% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)5.4× · Cheapest 25%
P/B1.00× · Cheaper than median
P/S (12 months)1.03× · Cheapest 25%
Price / free cash flow (fiscal year)32.2× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vieworks Co. Ltd (100120) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 35,295 KRW versus a price of 27,900 KRW, about +27% upside (undervalued).
What is the fair value of 100120?
Our model-based fair value for Vieworks Co. Ltd is 35,295 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 27,900 KRW.
What is the quality score of 100120?
Vieworks Co. Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vieworks Co. Ltd (100120)?
Our model-based price target is the fair value of 35,295 KRW (as of Nov 8, 2026) from 25 valuation models. Cautious scenario 20,913 KRW, optimistic scenario 56,161 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Vieworks Co. Ltd stock forecast for 2026?
Our models put fair value at 35,295 KRW, about +27% upside versus a price of 27,900 KRW (undervalued). Cautious scenario 20,913 KRW, optimistic scenario 56,161 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Vieworks Co. Ltd (100120)?
Vieworks Co. Ltd reported trailing-twelve-month revenue of about 244B KRW (latest available figure, as of Nov 8, 2026).
Does Vieworks Co. Ltd pay a dividend?
Vieworks Co. Ltd currently shows a dividend yield of 2.47% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Vieworks Co. Ltd (100120) and when is the ex-dividend date?
Vieworks Co. Ltd pays a dividend of 690.00 KRW per share a year, a dividend yield of 2.5%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 2009. The payout ratio is 13.7% of earnings. Free cash flow covers the dividend 1.31 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Vieworks Co. Ltd (100120)?
For today's price to be fair in a discounted-cash-flow model, Vieworks Co. Ltd would have to grow free cash flow by +25.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 100120 use?
Our models discount Vieworks Co. Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.40, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vieworks Co. Ltd that is +25.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Vieworks Co. Ltd (100120) delivered so far?
Over the past 5 years revenue at Vieworks Co. Ltd grew +8.4 % a year. The price currently implies free-cash-flow growth of +25.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vieworks Co. Ltd (100120) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Vieworks Co. Ltd (+25.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vieworks Co. Ltd (100120)?
The free-cash-flow yield on the price is 3.11 %: that much free cash flow Vieworks Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vieworks Co. Ltd (100120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vieworks Co. Ltd it is 35,295 KRW per share (as of Nov 8, 2026), against a price of 27,900 KRW. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Vieworks Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 100120 trades below its calculated fair value: price 27,900 KRW, fair value 35,295 KRW, a gap of about +27% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 100120?
No. The price is what the market pays today (27,900 KRW); the fair value is what the company's own numbers justify (35,295 KRW). For Vieworks Co. Ltd the two are 7,395 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vieworks Co. Ltd worth?
The market values Vieworks Co. Ltd at about 250B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 27,900 KRW; our models calculate a fair value of 35,295 KRW per share.
What do the bullish and bearish scenarios say about 100120?
Our models span a range for Vieworks Co. Ltd: cautious scenario 20,913 KRW, base 35,295 KRW, optimistic 56,161 KRW per share (as of Nov 8, 2026, price 27,900 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 100120?
Vieworks Co. Ltd trades at a price-to-earnings ratio of 5.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 35,295 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 12.7. Other multiples: P/B 1.0, P/S 1.0, EV/EBITDA 5.4.
How solid is the balance sheet of Vieworks Co. Ltd (100120)?
Balance-sheet figures for Vieworks Co. Ltd (as of Nov 8, 2026): return on equity 17.3%, debt of 0.00 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 100120 from its 52-week high?
Vieworks Co. Ltd trades at 27,900 KRW, about 15% below its 52-week high of 32,950 KRW and 59% above the low of 17,526 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 35,295 KRW is for.
Which stocks are comparable to Vieworks Co. Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vieworks Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 27,900 KRW, calculated fair value 35,295 KRW (+27%), Quality Score 61/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 100120 calculated?
We run Vieworks Co. Ltd through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 35,295 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Vieworks Co. Ltd currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vieworks Co. Ltd (100120)?
The closing price on Nov 6, 2026 was 27,900 KRW. Our model-based fair value is 35,295 KRW, about +27% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vieworks Co. Ltd right now?
The model range is unusually wide (20,913 KRW to 56,161 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Vieworks Co. Ltd
How large is the market capitalisation of Vieworks Co. Ltd (100120)?
The market capitalisation of Vieworks Co. Ltd is 250B KRW (≈ $185M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vieworks Co. Ltd (100120)?
The price-to-sales ratio of Vieworks Co. Ltd is 1.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vieworks Co. Ltd (100120)?
Earnings per share at Vieworks Co. Ltd are 5,050 KRW (price ÷ EPS = P/E 5.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vieworks Co. Ltd (100120)?
The dividend yield of Vieworks Co. Ltd is 2.5% (payout 13.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vieworks Co. Ltd (100120)?
The net margin of Vieworks Co. Ltd is 17.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vieworks Co. Ltd (100120)?
The return on equity (ROE) of Vieworks Co. Ltd is 17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vieworks Co. Ltd (100120)?
On an EBIT basis the return on assets of Vieworks Co. Ltd is 9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vieworks Co. Ltd (100120)?
The operating margin of Vieworks Co. Ltd is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vieworks Co. Ltd (100120)?
Revenue at Vieworks Co. Ltd is growing +1.9% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vieworks Co. Ltd (100120)?
Earnings per share at Vieworks Co. Ltd are growing +705% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vieworks Co. Ltd (100120) carry?
The net debt of Vieworks Co. Ltd is 37.4B KRW (fiscal year 2025, ≈ 4.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vieworks Co. Ltd in the live analysis
One click puts Vieworks Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026